The recommendations the InfantRisk Center provides are not meant to replace medical advice from your physician. The ultimate decision to breastfeed while taking medications should be based on an informed decision including available data, discussions between a mother, her physician, and the infants' pediatrician. The decision to take medications during pregnancy should be based available data and a discussion between a mother and her OB/GYN.
To ask a question, Create an Account or Login.
Cymbalta is rated a P3-unknown risk to fetus cannot be ruled out. This is a relatively new medication (approved by the FDA in 2004). There are no adequate or well controlled studies in pregnant women, therefore should only be used if the potential benefit to the mother justifies the potential risk to the fetus.
Mirtazapine is also a P3-unknown risk to fetus cannot be ruled out. Use during pregnancy is not expected to increase the risk of birth defects. Animal studies with rats and rabbits have revealed no evidence of teratogenic effects. One controlled study found no increase in birth defects attributable to mirtazepine at therapeutic doses, but did identify a slight increase in the rate of pre-term births as compared to women taking other antidepressants.
As with most medications use in the first trimester is almost always the most critical period. We recommend talking with you OB Dr prior to becoming pregnant to see what they recommend, perhaps trying to avoid the combination in the first trimester, but this is up to you and your OB Dr to discuss and determine.
Comment